pharmaphorum Podcast
By pharmaphorum
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by pharmaphorum
Category: Life Sciences
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 6
Reviews: 0
Episodes: 264
Description
pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for those who want insight into the future of health and medicine.
| Episode | Date |
|---|---|
|
Compliance baked into the design core: On AI in life sciences with Florian Schnappauf
|
Aug 07, 2025 |
|
Putting patients and their families first: Dr Corina Dutcus, post-ASCO 2025
|
Aug 05, 2025 |
|
Enhancing anti-tumour activity: A post-ASCO conversation with Dan Schmitt
|
Jul 31, 2025 |
|
Redefining the Future of Melanoma Treatment: Scancell's Bold Step Forward
|
Jul 29, 2025 |
|
Why Datavant bought Aetion, and what comes next, with Arnaub Chatterjee
|
Jul 24, 2025 |
|
Post-ASCO 25: Pamela Tenaerts on CGTs and digital-first long-term follow-up
|
Jul 22, 2025 |
|
Immune mediation, B-cell depletion, and female leadership – with Aoife Brennan
|
Jul 17, 2025 |
|
Ben Sidders on integrating causality in AI for R&D success
|
Jul 15, 2025 |
|
On nuclear medicine and oncology, SHINE technologies
|
Jul 10, 2025 |
|
Unicorns, AI, and the future of health: Highlights from HLTH Europe 2025
|
Jul 08, 2025 |
|
On patient-centric treatment decisions and the value of quantitative methodologies, in conversation with Marc Buyse
|
Jul 03, 2025 |
|
Maximising value by uniting the digital backbone: On a new Novo Nordisk and Veeva partnership
|
Jul 01, 2025 |
|
The changing landscape of drug clinical assessment: Tommy Bramley on the JCA
|
Jun 24, 2025 |
|
Precision, speed, impact: Evolving mass spectrometry for medical science
|
Jun 19, 2025 |
|
IMUNON at ASCO 2025: Changing the micro-tumour environment in advanced ovarian cancer
|
Jun 17, 2025 |
|
Treating primary bone cancer: The potential of listeria-based bioengineered bacterial immunotherapy
|
Jun 13, 2025 |
|
Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treatment with Tibsovo & Voranigo
|
Jun 05, 2025 |
|
Where innovation meets collaboration: Live from Manchester’s City labs 4.0
|
Jun 05, 2025 |
|
Live from ASCO 2025: Boehringer Ingelheim on unmet needs and oncology innovation
|
Jun 04, 2025 |
|
Bringing patients to research centres: Using AI to bring efficiencies forward
|
May 31, 2025 |
|
The need for a science-first mindset: The vaccine landscape today
|
May 23, 2025 |
|
EAPs: Market access outside of the US and Western Europe
|
May 19, 2025 |
|
The value of a partner, globally and locally
|
May 09, 2025 |
|
The ins and outs of HEOR – A lever for global health
|
May 06, 2025 |
|
Unpacking Trumps executive order on drug pricing with Alice Valder Curran
|
May 02, 2025 |
|
AI in drug development: The real hurdle is implementation
|
May 01, 2025 |
|
Patients as active consumers of care: AI-driven personalisation in pharma marketing
|
Apr 29, 2025 |
|
Driving the drug discovery pipeline: The value of organ-on-a-chip MPS
|
Apr 22, 2025 |
|
Intelligent regulatory compliance and improved patient outcomes
|
Apr 16, 2025 |
|
Prevention for a healthier, more productive society
|
Apr 15, 2025 |
|
Safeguarding the pharmaceutical supply chain
|
Apr 02, 2025 |
|
For the continuum of mental health we need a whole system, holistic 'healthspan'
|
Mar 31, 2025 |
|
IRA updates and making sense of the chaos in Washington, with Alice Valder Curran
|
Mar 20, 2025 |
|
GenAI and the revolution of drug development
|
Mar 05, 2025 |
|
Patient-focused manufacturing models for personalised therapies
|
Feb 28, 2025 |
|
On specialty pharmacies and prior authorisations
|
Feb 26, 2025 |
|
Paediatric rare diseases: Children are not small adults
|
Feb 20, 2025 |
|
Defining, building, and implementing in the next wave of biopharma R&D
|
Feb 13, 2025 |
|
Insights from JP Morgan Healthcare 2025: Key trends shaping the pharma industry
|
Feb 06, 2025 |
|
‘Show me the molecule’ – On synthetic biology and cutting through AI hype
|
Feb 04, 2025 |
|
Simulated clinical trial populations and AI scalability
|
Jan 30, 2025 |
|
Rare disease and the women's health gap
|
Jan 23, 2025 |
|
From science fiction to reality: AI in drug development
|
Jan 15, 2025 |
|
Precision medicine, NGS, and the quantum leap in biomarkers
|
Dec 18, 2024 |
|
Seeking effective, safe treatment for all with precision dosing
|
Dec 11, 2024 |
|
Seeking effective, safe treatment for all with precision dosing
|
Dec 03, 2024 |
|
CAR-T therapies: Faster, better, cheaper
|
Nov 26, 2024 |
|
Looking to history to prepare for America’s uncertain future
|
Nov 19, 2024 |
|
Next gen wearables: Transforming remote patient care
|
Nov 12, 2024 |
|
From neurosurgery to focused ultrasound: Not if, but when
|
Nov 05, 2024 |
|
A journey from personal to public: Digital health passports today
|
Oct 29, 2024 |
|
Access to genomic surveillance: Open science and public health
|
Oct 16, 2024 |
|
Advancing Precision Care For All
|
Oct 09, 2024 |
|
Investment outlook: Key takeaways from LSX USA
|
Oct 04, 2024 |
|
Oncology today: Eversana and pharmaphorum at ESMO 2024
|
Sep 25, 2024 |
|
Medicare drug pricing negotiations: What comes next?
|
Sep 12, 2024 |
|
The Life Sciences Generative AI Council and a sustainable technological future
|
Sep 05, 2024 |
|
Can self-navigating ADCs replace chemotherapy in the future?
|
Aug 28, 2024 |
|
Structuring the unstructured: Deterministic AI and white box data cleanliness
|
Aug 20, 2024 |
|
People need to know how to use AI now
|
Aug 13, 2024 |
|
Chronic cough and the patient voice
|
Aug 06, 2024 |
|
Approaching the regulatory world with passion: CERs and EU MDR processes
|
Jul 31, 2024 |
|
Patient engagement throughout the product lifecycle
|
Jul 25, 2024 |
|
The empowerment of data and predictive outcome models
|
Jul 23, 2024 |
|
The burden of diabetic vision loss in the West
|
Jul 18, 2024 |
|
Tips for on-time tech transfers that stay below budget
|
Jul 18, 2024 |
|
Clinical trial trends and the rise of site networks
|
Jul 11, 2024 |
|
A spectrum of obesity requires precision
|
Jul 10, 2024 |
|
The power and potential of regenerative medicine
|
Jul 02, 2024 |
|
Leveraging data and AI for clinical trial success
|
Jun 28, 2024 |
|
The future of fertility and the vaginal microbiome
|
Jun 25, 2024 |
|
Sustainable innovation for patients, people, and planet
|
Jun 21, 2024 |
|
The new frontier of microbiome-directed human health
|
Jun 18, 2024 |
|
Global medicines and the future outlook
|
Jun 13, 2024 |
|
Purity, potency, and safety – affordably – in stem cell therapy
|
Jun 11, 2024 |
|
The art of software
|
Jun 05, 2024 |
|
Move over CAR-T: The potential of NK cells in cell therapy
|
May 30, 2024 |
|
Working for a mature form of genomic medicines
|
May 29, 2024 |
|
Challenges and opportunities in synthetic clinical trials
|
May 23, 2024 |
|
The commercialisation of quantum science in pharma
|
May 21, 2024 |
|
Conference report: Reuters Pharma Europe
|
May 16, 2024 |
|
In vitro gametogenesis: the science has to be right, and it has to be safe
|
May 14, 2024 |
|
Proving ROI for digital endpoints
|
May 09, 2024 |
|
Clinical trials: their design, location, and, potentially, their simulation
|
May 08, 2024 |
|
Pace, acceleration, and precision are the name of the game
|
May 02, 2024 |
|
Technology working as the puzzle piece to bring better outcomes to patients
|
Apr 30, 2024 |
|
Is precision psychiatry possible?
|
Apr 25, 2024 |
|
Encouraging early engagement to revitalise Europe’s pharmaceutical landscape
|
Apr 23, 2024 |
|
Predictions for AI in mental health in the coming year
|
Apr 18, 2024 |
|
Fixing clinical trial data management
|
Apr 11, 2024 |
|
Harnessing the velocity of biopharmaceutical advances
|
Apr 09, 2024 |
|
Conference report: Reuters Pharma USA
|
Apr 04, 2024 |
|
The future of AI: Machine learning working together with scientific expertise
|
Apr 02, 2024 |
|
Understanding the politics of drug pricing in the United States
|
Mar 28, 2024 |
|
Female leadership and lessening disease burden
|
Mar 26, 2024 |
|
The unique clinical trial challenges faced by digital therapeutics
|
Mar 21, 2024 |
|
The unmentionables: Challenging inequalities in women’s health
|
Mar 19, 2024 |
|
The next chapter for AI protein structure prediction
|
Mar 14, 2024 |
|
Avoiding the data swamp: The transformative power of AI
|
Mar 12, 2024 |
|
How natural language processing can make a difference in pharma
|
Mar 07, 2024 |
|
Transitioning from traditional surgical methods to the innovative use of stem cells.
|
Mar 05, 2024 |
|
The 2024 biopharma M&A landscape: An overview
|
Feb 29, 2024 |
|
Accelerating the process, transforming therapies and advancing precision medicine
|
Feb 27, 2024 |
|
Applying genetics to chemistry to find new small molecules
|
Feb 22, 2024 |
|
Opening the digital front door to advanced healthcare
|
Feb 20, 2024 |
|
Pharmaceutical research in space
|
Feb 15, 2024 |
|
Precision medicine in mental health - one size really doesn’t fit all
|
Feb 13, 2024 |
|
Where are the pharma voices in US politics?
|
Feb 08, 2024 |
|
A clearer harmony and attractiveness for EU Clinical Trials Regulation
|
Feb 06, 2024 |
|
Making connections and getting noticed as a biotech start-up
|
Feb 01, 2024 |
|
Getting down to the nitty gritty of actively creating healthier societies
|
Jan 30, 2024 |
|
How manufacturing keeps pace with innovation in cell and gene therapy
|
Jan 25, 2024 |
|
Fixing the inequity of drug access outside of the US
|
Jan 23, 2024 |
|
Key themes from JP Morgan
|
Jan 18, 2024 |
|
Prediction is very difficult, especially if it’s about the future
|
Jan 16, 2024 |
|
Promoting value-added medicines and renovating old medicines smartly
|
Jan 11, 2024 |
|
Digitisation of drug R&D: Avoiding new for novelty’s sake
|
Jan 09, 2024 |
|
The problems of animal research for human medicine and the alternatives
|
Jan 04, 2024 |
|
The race to develop innovative products and supply chain solutions
|
Dec 30, 2023 |
|
The smart-design evolution of the laboratory space
|
Dec 29, 2023 |
|
Investing in the gleams of positivity and hope for life sciences innovation
|
Dec 28, 2023 |
|
Looking to the future of UK medical device exports
|
Dec 27, 2023 |
|
Exploring the reasons behind increasing burdens on clinical research sites
|
Dec 26, 2023 |
|
An investor’s perspective on bio and tech
|
Dec 21, 2023 |
|
Why digital therapeutics (DTx) are effective and safe, but not being prescribed
|
Dec 19, 2023 |
|
AI drug discovery: Where we are and where we’re going
|
Dec 14, 2023 |
|
Retaining the human element in healthcare services whilst embracing the potential of robotics
|
Dec 12, 2023 |
|
Bringing women’s health up to speed for 21st Century human healthcare
|
Dec 07, 2023 |
|
Creating a future where the healthcare ecosystem works for everyone
|
Dec 05, 2023 |
|
Key themes from Frontiers Health 2023, with the pharmaphorum team
|
Nov 30, 2023 |
|
Reducing the stigma attached to psychedelics
|
Nov 28, 2023 |
|
How birth tissue donations are fuelling the cell therapy revolution
|
Nov 23, 2023 |
|
Immunometabolism: Providing a new era of targeted medicine
|
Nov 21, 2023 |
|
Retaining the human element of AI within pharma and healthcare
|
Nov 16, 2023 |
|
Resilience, empathy, and gratitude. A personal battle with breast cancer.
|
Nov 14, 2023 |
|
The ‘elegant science’ in achieving the promise of ADCs
|
Nov 07, 2023 |
|
Understanding the importance of the whole person in clinical research
|
Nov 02, 2023 |
|
Why medical weight loss is more complicated than GLP-1s
|
Oct 27, 2023 |
|
Creating behavioural change through incremental, small steps
|
Oct 24, 2023 |
|
How AI can bolster each step of the clinical trial journey
|
Oct 19, 2023 |
|
Focussing on finding value in health sciences marketing
|
Oct 17, 2023 |
|
How big pharma cares for its own
|
Oct 12, 2023 |
|
Embracing the challenges and opportunities of digital health
|
Oct 10, 2023 |
|
How AI and omnichannel are transforming pharma marketing
|
Oct 05, 2023 |
|
Digital therapeutics at a turning point: What we heard at DtX East
|
Oct 03, 2023 |
|
Understanding and addressing care disparities in rare cancers
|
Sep 28, 2023 |
|
Turning drug development on its head
|
Sep 21, 2023 |
|
GLP-1 Weight loss drugs: An overview and update
|
Sep 14, 2023 |
|
Biopharma’s rapid transition to omnichannel marketing
|
Sep 07, 2023 |
|
Partnering for holistic care
|
Aug 31, 2023 |
|
Mapping the landscape of clinical trial regulation
|
Aug 25, 2023 |
|
Preparing for the tsunami of healthcare data approaching
|
Aug 15, 2023 |
|
Alzheimer’s drugs: An overview and update
|
Aug 10, 2023 |
|
Suffering beyond physical effects: inequalities and taboos in prostate cancer
|
Aug 01, 2023 |
|
Collaborative perseverance to bring change to medicine access
|
Jul 28, 2023 |
|
Botanicals in pharma: Potential and pitfalls
|
Jul 27, 2023 |
|
Clinical trial diversity: An update
|
Jul 13, 2023 |
|
Changing personnel dynamics in the pharma world
|
Jul 06, 2023 |
|
Retaining the human quality of healthcare in DTx
|
Jul 05, 2023 |
|
Focusing on predictability and execution in digital trials
|
Jun 28, 2023 |
|
Genetic testing update with 23andMe’s Noura Abul-Husn
|
Jun 16, 2023 |
|
Headlines and hot topics from ASCO and BIO
|
Jun 09, 2023 |
|
The precision element at the heart of digital transformation
|
May 30, 2023 |
|
AI in drug development: A reality check
|
May 25, 2023 |
|
Epiphany moments in an industry starved of insights
|
May 22, 2023 |
|
A closer look at gene therapy with PTC Therapeutics
|
May 18, 2023 |
|
WWD: Ready, Set, Food! CEO, Daniel Zakowski
|
May 11, 2023 |
|
The Hidden Burden of Stigmatised Health Conditions
|
May 02, 2023 |
|
Creating healthier futures - Reuters Pharma Barcelona 2023
|
May 02, 2023 |
|
Inside the new world of healthcare data
|
Apr 20, 2023 |
|
Restoring sensitivity to targeted therapies
|
Apr 14, 2023 |
|
Insulin costs & pharma manufacturing
|
Apr 13, 2023 |
|
What the low impact of Humira biosimilars teaches us about drug prices
|
Apr 06, 2023 |
|
Transforming healthcare: Nils Bottler and Paul Tunnah
|
Mar 30, 2023 |
|
Challenges and opportunities with plasma-derived therapies
|
Mar 23, 2023 |
|
CinCor Pharma: A small pharma’s journey to acquisition
|
Mar 10, 2023 |
|
AI trends in 2023
|
Mar 02, 2023 |
|
Accelerating digital healthcare, with VITA
|
Mar 01, 2023 |
|
Investing in healthcare’s future, with Paul Tunnah and Elia Stupka
|
Feb 17, 2023 |
|
Solving problems in pathology data, with Nathan Buchbinder
|
Feb 09, 2023 |
|
How Moderna kept diversity in mind amid vaccine development
|
Jan 26, 2023 |
|
Key themes from JP Morgan, with Paul Tunnah
|
Jan 12, 2023 |
|
Cancer control in a time of crisis
|
Jan 05, 2023 |
|
The scattered seeds of the beginnings of change
|
Dec 30, 2022 |
|
A few of the 2022’s biggest pharma trends
|
Dec 29, 2022 |
|
Exploring the importance we play in our own health maintenance
|
Dec 23, 2022 |
|
Focusing on the evolution of biotechnology and R&D
|
Dec 22, 2022 |
|
Innovations in Real-World Evidence (live from PharmStars)
|
Dec 15, 2022 |
|
Continuing to keep COVID-19 at bay
|
Dec 08, 2022 |
|
Can VR technology make physical therapy fun
|
Dec 01, 2022 |
|
Exploring a united vision for British pharma at Anthropy
|
Nov 28, 2022 |
|
What we heard and saw at HLTH22, with Matthew Holt
|
Nov 24, 2022 |
|
Disrupting the standard of healthcare for Bangladesh
|
Nov 18, 2022 |
|
How immersive audio can be a therapeutic tool
|
Nov 17, 2022 |
|
A new hope in cachexia and an outsider’s view on pharma
|
Nov 10, 2022 |
|
Why is digital health so challenging for big tech?
|
Nov 03, 2022 |
|
Live from Frontiers Health 2022 - the pharmaphorum podcast
|
Oct 27, 2022 |
|
Live from Reuters Pharma 2022 - the pharmaphorum podcast
|
Oct 20, 2022 |
|
Building agile partner relationships at a vaccine-focused biotech
|
Oct 13, 2022 |
|
Understanding the tumour micro-environment – the pharmaphorum podcast
|
Oct 06, 2022 |
|
How a once-weekly insulin could disrupt diabetes management
|
Sep 22, 2022 |
|
How these parents of a child with a rare disease are making precision medicine work for them
|
Sep 08, 2022 |
|
AI-derived cancer vaccines
|
Aug 25, 2022 |
|
Challenges and opportunities in the off-patent sector
|
Aug 11, 2022 |
|
Building a digital therapeutic for paediatric behavioural health opioids
|
Jul 28, 2022 |
|
Gene silencing and mRNA: breakthroughs and barriers
|
Jul 14, 2022 |
|
Rethinking pharmaceutical pain management beyond opioids
|
Jul 05, 2022 |
|
Why diverse clinical trials matter
|
Jun 16, 2022 |
|
Where pharma stands on patient centricity, engagement, and trust
|
Jun 06, 2022 |
|
How pharma can spur innovation and promote health equity in mental health
|
May 19, 2022 |
|
Innovative solutions to the drug pricing crisis: the pharmaphorum podcast
|
Apr 29, 2022 |
|
Big data and how it can change the game in pharma: the pharmaphorum podcast
|
Mar 23, 2022 |
|
The year ahead in digital health and life sciences: the pharmaphorum podcast
|
Feb 10, 2022 |
|
The evolution of clinical trials: the pharmaphorum podcast
|
Jan 14, 2022 |
|
Patient engagement processes: the pharmaphorum podcast
|
Dec 17, 2021 |
|
Real-world evidence and qualitative research: the ELICIT podcast
|
Nov 25, 2021 |
|
Merck on trends in oncology: the pharmaphorum podcast
|
Nov 12, 2021 |
|
Sandoz’s Pierre Bourdage on biosimilars: the pharmaphorum podcast
|
Nov 05, 2021 |
|
Patient engagement strategies: the pharmaphorum podcast
|
Oct 29, 2021 |
|
BMS’ Catherine Owen on pharma commercialisation: the pharmaphorum podcast
|
Oct 15, 2021 |
|
Novartis’ Amit Nastik on COVID’s supply chain impact: the pharmaphorum podcast
|
Oct 04, 2021 |
|
Virtual engagement and collaborations: the pharmaphorum podcast
|
Sep 22, 2021 |
|
Biotech Insight podcast: Overcoming planning challenges in oncology
|
Sep 08, 2021 |
|
Vertex senior country manager Nicola Massey: the pharmaphorum podcast
|
Aug 23, 2021 |
|
Regenerative medicine and COVID: the pharmaphorum podcast
|
Aug 13, 2021 |
|
Pharmacy and clinical research: the pharmaphorum podcast
|
Jun 30, 2021 |
|
Pharma’s post-COVID prospects: the pharmaphorum podcast
|
May 28, 2021 |
|
Galapagos UK’s Michael Smyth on COVID and RNA-based tech: the pharmaphorum podcast
|
Apr 30, 2021 |
|
Big data and cell therapy development: the pharmaphorum podcast
|
Apr 20, 2021 |
|
GSK on COVID and vaccine development: the pharmaphorum podcast
|
Mar 31, 2021 |
|
The meaning of digital innovation: the pharmaphorum podcast
|
Mar 23, 2021 |
|
New ways to treat COVID: the pharmaphorum podcast
|
Mar 12, 2021 |
|
The Alderley Park Discovery Podcast: The journey to accessing science funding and investment
|
Mar 08, 2021 |
|
Roche on COVID healthcare and testing: the pharmaphorum podcast
|
Feb 26, 2021 |
|
Richard Francis discusses his new role as Purespring’s CEO: pharmaphorum podcast
|
Feb 12, 2021 |
|
AstraZeneca’s Rebekah Martin on diversity and inclusion: the pharmaphorum podcast
|
Jan 29, 2021 |
|
The Alderley Park Discovery Podcast: Life science skills, staffing and support
|
Jan 05, 2021 |
|
J&J and medical device innovation: the pharmaphorum podcast
|
Dec 21, 2020 |
|
Biotech trends in COVID era: the pharmaphorum podcast
|
Nov 30, 2020 |
|
GSK and eosinophil research: the pharmaphorum podcast
|
Oct 30, 2020 |
|
Gitte Aabo on telemedicine and her time at LEO Pharma: the pharmaphorum podcast
|
Sep 28, 2020 |
|
The Alderley Park Discovery Podcast: COVID testing and the Lighthouse Lab
|
Sep 15, 2020 |
|
Alnylam, gene-silencing and biotech in 2020: the pharmaphorum podcast
|
Aug 27, 2020 |
|
Novartis, company culture and COVID-19: the pharmaphorum podcast
|
Jul 30, 2020 |
|
Amgen and science education: the pharmaphorum podcast
|
Jun 30, 2020 |
|
UK pharma leadership and COVID-19: the pharmaphorum podcast
|
May 29, 2020 |
|
Eisai and Alexa skills in epilepsy: the pharmaphorum podcast
|
Apr 02, 2020 |
|
Digital health and interoperability: the pharmaphorum podcast
|
Mar 09, 2020 |
|
Roche, big data and patient outcomes: the pharmaphorum podcast
|
Jan 08, 2020 |
|
Pfizer and the UK cancer landscape: the pharmaphorum podcast
|
Dec 11, 2019 |
|
Life sciences leadership: the pharmaphorum podcast
|
Nov 14, 2019 |
|
AstraZeneca and lung cancer: the pharmaphorum podcast
|
Aug 07, 2019 |
|
Lung cancer’s patient information gap: the pharmaphorum podcast
|
Aug 06, 2019 |
|
The state of UK drug discovery: the pharmaphorum podcast
|
Jul 19, 2019 |
|
Addressing global health challenges: the pharmaphorum podcast
|
Jun 19, 2019 |
|
Gene therapy and market access: the pharmaphorum podcast
|
May 31, 2019 |
|
AMR research and Matoke Pharma: the pharmaphorum podcast
|
May 13, 2019 |
|
GSK and digital disruption: the pharmaphorum podcast
|
Apr 05, 2019 |
|
Ipsen on neurotoxin research: the pharmaphorum podcast
|
Mar 28, 2019 |
|
Successful medical marketing teams: the pharmaphorum podcast
|
Feb 22, 2019 |
|
Biotech strategy and nanomedicine: the pharmaphorum podcast
|
Dec 21, 2018 |
|
Commercialising orphan drugs: the pharmaphorum podcast
|
Nov 20, 2018 |
|
The future biosimilar landscape: the pharmaphorum podcast
|
Oct 16, 2018 |
|
Nimble consumer healthcare innovation: the pharmaphorum podcast
|
Sep 14, 2018 |